# Risk-adapted Therapy for Primary Acute Myeloid Leukemia

> **NCT04687098** · PHASE2 · COMPLETED · sponsor: **Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias** · enrollment: 1034 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Idarubicin
- **DRUG:** Ara-C
- **DRUG:** G-CSF
- **PROCEDURE:** Allogeneic matched or unrelated donor transplant.
- **PROCEDURE:** Autologous peripheral blood stem cell transplant
- **PROCEDURE:** Measurable residual disease

## Key facts

- **NCT ID:** NCT04687098
- **Lead sponsor:** Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-01
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-11-10
- **Target enrollment:** 1034 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04687098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04687098, "Risk-adapted Therapy for Primary Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04687098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*